Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6935-6942

  Dai, Jie ^a   Kong, Yan ^a   Si, Lu ^a   Chi, Zhihong ^a   Cui, Chuanliang ^a   Sheng, Xinan ^a   Mao, Lili ^a   Li, Siming ^a   Lian, Bin ^a   Yang, Ruifeng ^b   Liu, Shujing ^b   Xu, Xiaowei ^b   Guo, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CRENOLANIB; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CELL PROLIFERATION; CHINESE; DRUG POTENCY; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MELANOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; AGED; BENZAMIDES; BENZIMIDAZOLES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PIPERAZINES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84890603543     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1266     Document Type: Article

References (41)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/19752009pops09/, based on November 2011 SEER data submission, posted to the SEER website, April 2012.
2. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 2010;74:27-39.
3. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multi-centre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65.
5. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29: 2904-9.
6. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34.
7. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:782-9.
8. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012;26:1131-55.
9. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011;17:1684-91.
10. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012;48:94-100.
11. Marius R, Anca MC. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals 2010;3:572-99.
12. Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 2005;8:75-83. (Pubitemid 40797958)
13. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23: 5357-64. (Pubitemid 46206989)
14. Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 2006;27:664-71. (Pubitemid 43372895)
15. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008;22:1999-2010.
16. Hiwatari M, Taki T, Tsuchida M, Hanada R, Hongo T, Sako M, et al. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor alpha (PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22). Leukemia 2005;19:476-7. (Pubitemid 40403334)
17. Barnhill RL, Xiao M, Graves D, Antoniades HN. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 1996;135:898-904. (Pubitemid 26397917)
18. Curtin JA, Pinkel D, Bastian BC. Absence of PDGFRA mutations in primary melanoma. J Invest Dermatol 2008;128:488-9.
19. Terada T. Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases. Int J Clin Oncol 2010; 15:453-6.
20. Wallander ML, Layfield LJ, Emerson LL, Mamalis N, Davis D, Tripp SR, et al. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol 2011;24:1031-5.
21. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21: 4342-9. (Pubitemid 46621810)
22. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
23. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE III, Daud A, et al. Melanoma, version 2. 2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:395-407.
24. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Rama-chandran A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012;18:4375-84.
25. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, et al. Identification of mutations in the coding sequence of the proto-onco-gene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44. (Pubitemid 23304537)
26. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21. (Pubitemid 33091601)
27. Braggio E, Braggio Dde A, Small IA, Lopes LF, ValadaoM, Gouveia ME, et al. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Anticancer Res 2010;30:2407-14.
28. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, et al. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest 2010;90:1285-94.
29. Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gau-mann A, et al. Minute gastric sclerosing stromal tumors (GIST tumor-lets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31:113-20. (Pubitemid 46036910)
30. Bai C, Liu X, Zheng JM, Qiu C, Zhu Y, Xu J, et al. A novel PDGFRA mutation in gastrointestinal stromal tumours, L839P, is sensitive to imatinib in vitro. Oncol Lett 2012;3:1139-43.
31. National Cancer Institute. The Cancer Genome Atlas data portal. 2013 [accessed 2013 Jul 14]. Available from: http://cancergenome.nih.gov/.
32. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34. (Pubitemid 32786275)
33. Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006;108:3504-13.
34. Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007;6:1159-66. (Pubitemid 46554587)
35. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64.
36. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
37. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
38. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012;11:873-86.
39. Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 2010;23:210-5.
40. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, et al. KIT gene mutations andcopy number inmelanoma subtypes. Clin Cancer Res 2008;14:6821-8.
41. Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2012;29:1765-72.